2 results
Approved WMOCompleted
Lu AF28996 is an orally administered investigational compound of a potent, long-acting dopamine agonist, Lu AA40326, currently under development by H. Lundbeck A/S for the treatment of Parkinson*s disease (PD). Primary Objective:to investigate the…
Approved WMOPending
The primary objective of this study is to investigate the local tolerability of isoniazid inhalation by wet nebulization at ascending dosages. Secondary objective is systemic pharmacokinetics of inhaled isoniazid compared to intravenous dose…